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SUMMARY
CR2, the receptor for the C3d fragment of the third complement component and for Epstein-Barr
virus (EBV) has been shown, on mouse B cells, to be involved in the control of B-cell proliferation by
acting as a receptor for macrophage-derived growth factors. We examined whether the growth of a
Burkitt lymphoma cell line, RAJI, could be influenced by ligands of human CR2. In serum-free
culture, purified human C3d, as well as three monoclonal antibodies to distinct epitopes on human
CR2, were capable of enhancing the growth rate of RAJI cells two to five-fold. This effect could not
be observed if even trace amounts of serum were present in the culture medium. Simultaneous
addition of pairs of antibodies did not enhance the growth rate, suggesting that a particular
engagement ofCR2 may be critical in order to induce a stimulatory effect. These results indicate that
in a homologous serum-free human B-cell system human C3d as well as monoclonal antibodies to
human CR2 can induce B-cell proliferation and that CR2-mediated triggering of B cells can be
induced via epitopes other than the C3d-binding site. In addition we conclude that-unlike normal
human B cells-at least some human B-lymphoma cells respond to CR2-mediated stimuli in the
absence of any T-cell derived factors. Therefore the control mechanisms exerted through CR2 must
still be intact on these autonomously growing cells.
INTRODUCTION
The receptor for the C3d fragment of the third complement
component, CR2, a glycoprotein of 145,000 MW (Barel,
Charriaut & Frade, 1981; Weis, Tedder & Fearon, 1984;
Micklem, Sim & Sim, 1984), has been shown recently to act also
as the receptor for the Epstein-Barr virus (EBV) (Frade et al.,
1985a; Fingeroth et al., 1984; Nemerow et al., 1985b) and to be
involved in the control of B-cell proliferation (Nemerow,
McNaughton & Cooper, 1985a; Frade et al., 1985b; Melchers et
al., 1985; Petzer et al., 1988). In the case ofmurine B cells kept in
serum-free culture it was shown that engagement of this
receptor by cross-linked C3d enables the preactivated B cell to
progress through the S-phase of its cycle. An additional T-cell-
derived factor then provides the signal necessary for the
beginning of mitosis (Melchers et al., 1985, 1986). For human B
cells it was also shown that stimulation of B cells via CR2
requires the presence of a T-cell-derived factor (Frade et al.,
1985b; Petzer et al., 1988). However, the exact point of action of
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CR2 has not yet been established in the human system, although
one would expect it to be similar to that described above.
Human B-cell lines established from Burkitt's lymphoma or
obtained by transformation of normal B cells with EBV in vitro
are capable of growing in an autonomous fashion in vitro. It has
been shown that autocrine growth factors produced by these
cells contribute to their autonomous growth (Gordon et al.,
1984a,b; Blazar, Sutton, & Strome, 1983). Similarly, the
inappropriate expression of some oncogenes is in some cases
thought to render the cell independent of external stimuli and
thus to bypass physiological control mechanisms (Rapp et al.,
1985; Kaczmarek et al., 1985). In this study we employed a
serum-free culture system to investigate whether autonomously
growing Burkitt's lymphoma cell lines would still be susceptible
to stimuli transmitted via CR2, whether human C3d would,
under such conditions, stimulate human B cells and if the
triggering of human B cells would occur via other epitopes than
the binding site for C3d.
MATERIAL AND METHODS
Cell culture
The human Burkitt lymphoma cell line, RAJI, was grown in
RPMI-1640 supplemented with 10% fetal calf serum (FCS),
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glutamine, penicillin, streptomycin and fungizone. For this
study the cells were adapted to serum-free culture by reducing
the serum concentration to 5% for 3 days, then to 1% for
another 3 days and then washing them three times in phosphate-
buffered saline (PBS) and resuspending them in RPMI-1640
containing 0 25% bovine serum albumen (BSA) (Cohn Fraction
V, No. A-4503 Sigma, St Louis, MO) as the only protein source.
For stimulation assays, RAJI cells adapted to serum-free
culture for I week were cultured in 24-well plates or 96-well
microtitre culture plates (Greiner) for 7 days, at a concentration
of 1 x 105 cells/ml (I x 105 or 2 x 104 cells/well, respectively) in
the presence of several concentrations of purified human C3d or
monoclonal antibodies. Antibodies and C3d were either present
in solution or bound to the bottom of the culture wells. For
binding to culture wells, 200 pi or 50 p1 of PBS (10 mm Na
phosphate, 140 mm NaCl) containing antibodies in the concen-
trations indicated in the test were added to a 1 -ml or 200-pl
culture well, respectively, and the plate incubated for I hr at
room temperature. The contents were then aspirated and the
wells saturated three times for 20 min at room temperature with
400 p1 and 100 p1, respectively, of 0 25% BSA in RPMI-1640.
The cells were counted daily from Day 2 to 7 and cell
viability was determined by trypan blue exclusion. Thymidine
(TdR) incorporation was determined on Day 3 by pulsing the
cells with 0-5 pCi [3H]TdR/well for 4 hr. Stimulation experi-
ments were always set up in triplicate.
Monoclonal antibodies to CR2
As reported previously (Petzer et al., 1988), the mouse IgGI
anti-CR2 antibodies 1C8,2G7 and 6F7 are directed against
three distinct epitopes localized on a 28,000 MW tryptic
fragment of CR2. A fourth antibody, I F8, recognizes the same
epitope as 2G7. The 28,000 MW fragment is itself derived from
the 72,000 MW tryptic fragment of CR2 carrying the binding
site for C3d. Antibodies used in this study were purified from
ascites by repeated precipitation (three times) with Na2SO4
followed by anionic ion-exchange chromatography on HPLC
(LKB Bromma, 2133-100, Ultropac Column, TSK DEAE-
3SW, 7-5 x 150 mm).
Purification of C3d
One litre of human plasma from outdated blood was incubated
at 370 for 7 days in the presence of 0-1% NaN3 and then
fractionated by sequential precipitation with 3-5% and 15%
polyethyleneglycol. The 15% pellet was redissolved in 10 mm
Na-phopphate buffer, pH6 8 and applied to a DEAE-Sephacel
column (Pharmacia) (gel bed I 1). The column was washed
extensively with running buffer and then developed with a
2 x 2-5 1 gradient of 0-500 mm NaCl. Fractions containing C3
were identified by Ouchterlony and further analysed on Western
blots stained with an antiserum to human C3d. Fractions
containing the 43,000 MW C3dg and the 35,000 C3dMW band
were pooled, concentrated and further purified by chromato-
graphy on a G-100 column (1 x 100 cm). Fractions containing
C3dg and C3d were pooled separately.
Immunofluorescence and FACS analysis
Immunofluorescence with anti-CR2 antibodies was performed
according to standard methods using a FITC-labelled goat anti-
mouse IgG conjugate (Tago, Hamburg, FRG). In some experi-









Figure 1. Enhancement ofthe growth ofRAJI cells in serum-free culture
by C3d. RAJI cells, adapted to serum-free culture as described in the
Materials and Methods, were grown in the presence (A-A) or absence
(0-0) of purified human C3d, which had been added to the culture (a)
or attached to the bottom of the culture plate (b). Values shown are the
means of triplicate wells and represent the result of one of three similar
experiments. Variability within one experiment was generally less than
15%.
1988) was used in combination with streptavidin-conjugated
phycoerythrin (Becton-Dickinson). Monoclonal antibody
MAH-3, directed against factorH (Schulz et al., 1984), was used
as a control. Analysis by flow cytometry was done on a FACS
III (Becton-Dickinson). Excitation was at 488 nm with an argon
laser and emission was measured with band pass filter 530/30.
The logarithmically amplified fluorescence signal is represented
on a 120-channel scale covering about three decades. At least 104
cells were analysed in each experiment.
RESULTS
Purified C3d enhances the growth of RAJI cells in serum-free
culture
RAJI cells were adapted to serum-free culture, as described in
the Material and Methods, over a period of 7 days. We could
keep RAJI cells inserum-free culture for up to 4 weeks with a
viability between 80% and 90%. Under these conditions RAJI
cells grew more slowly and reached a maximal culture density of
6-8 x 105 cells/ml (Fig. 1), i.e. about half the density obtained in
serum-containing media. After 7 days in serum-free culture
human C3d was added. In the presence of C3d RAJI cells
reached a two to three-fold higher density (Fig. 1) and showed
two to three times faster growth rate as assessed by TdR
incorporation (Fig. 3).
This effect could be observed both with fluid-phase C3d and
with C3d that had been bound previously to the bottom of the
culture wells. However, C3d no longer enhanced the growth rate
of RAJI cells in the presence of as little as 0-2% FCS.
Monoclonal antibodies to CR2 mimick the effect of C3d on the
growth rate of RAJI cells
Culturing RAJI cells in the presence of several concentrations of
monoclonal antibodies to three distinct epitopes on CR2 had a
similar effect on the growth rate as well as the maximal culture
density as did C3d. (Figs 2 and 3). An antibody to human IgM
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Figure 2. Enhancement ofthe growth ofRAJI cells in serum-free culture
by monoclonal antibodies to CR2. RAJI cells, adapted to serum-free
cultures described in the Materials and Methods, were grown without
(0-0) or in the presence of monoclonal antibodies to surface IgM
(clone 89; 0-0) and three distinct epitopes ofCR2: (A-A), clone 1C8;
(0-0), clone 2G7; (x- x ), clone 6F7. Antibodies were either added
to the culture (a) or attached to the bottom of the culture plate (b).
Values shown are the means of triplicate wells and represent the result of
one of four similar experiments. Variability within one experiment was
generally less than 15%.
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Figure 3. Effect on RAJI cell growth of combinations of monoclonal
antibodies to CR2. RAJI cells in serum-free culture were grown in the
presence of one single or pair-wise combinations of monoclonal
antibodies to distinct epitopes of CR2 and their growth rate assessed by
thymidine incorporation (0 5 pCi/well, 4-hr pulse) on Day 3. Shown are
the means of triplicate samples, which varied by less than 10%. The
figure represents one out of two similar experiments.
Simultaneous engagement of two epitopes on CR2 abolishes
increased proliferation
The pair-wise addition of monoclonal antibodies to three
different epitopes on CR2 does not induce the increase in
proliferation that all three antibodies were able to induce on
their own (Fig. 3). As single antibodies still exerted their
stimulating effect in concentrations 10-fold higher than the
concentrations used when two antibodies were added simulta-
neously, this observation cannot be explained by an overstimu-
lation due to excessive doses of antibodies.
The expression of CR2 on RAJI cells is enhanced by a factor in
FCS but not by C3d or monoclonal antibodies to CR2
Determining the effect of FCS on the quantitative expression of
CR2 on RAJI cells we found that in the presence of serum RAJI
1000 -(a) FCS (b) BSA
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Figure 4. Expression ofCR2 on RAo cells grown in serum-free and in
serum-containing culture. RAJI cells grown in serum-free culture (b) or
in RPMI-medium containing 10% FCS (a) were stained in indirect
immunofluorescence using monoclonal antibody I F8, directed at the
same epitope on CR2, which is recognized by 2G7 (Petzer et al., 1988)
and MAH-3 directed at complement factor H (MAH-3) as a control,
and analysed by flow cytometry. Fluorescence intensity is displayed
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Figure 5. Expression ofCR2 on RAJI cells is not up-regulated by ligands
ofCR2. RAJI cells were grown for 3 days in serum-free culture alone (a)
or in the presence of stimulating concentrations of C3d (1 ug/ml; b), or
monoclonal antibodies to CR2 2G7 (1 yg/ml; c) and 6F7 (1 ug/ml; d).
Cells were harvested, washed and stained with biotinated 6F7 or
biotinated monoclonal antibody to factor H (MAH-3) as a control,
followed by avidin-conjugated phycoerythrin and analysed by flow-
cytometry.
cells expressed five to 10-fold more CR2 than in the absence of
serum (Fig. 4). In order to test whether C3 or C3 fragments
present in serum might induce a similar increase of CR2, we
measured the expression of CR2 on RAJI cells cultured for 4
days in serum-free culture in the presence of stimulating
concentrations of C3d or monoclonal antibodies to CR2. As
shown in Fig. 5, neither C3d (b) nor a monoclonal stimulating
antibody to CR2 (2G7, c) increased the expression of CR2 as
measured in immunofluorescence using a biotinated antibody
recognized a different epitope (6F7). The specificity of the
fluorescence in this experiment is demonstrated in Fig. 5d where
monoclonal antibody 6F7 (unconjugated) was used to stimulate
RAJI cells which were then stained with the same antibody
conjugated to biotin and avidin-conjugated phycoerythrin.
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cell surface during the culture the same antibody (in its
biotinated form) stains RAJI cells only very weakly. These
experiments would indicate that CR2 is most likely not up-
regulated by its ligand but by another factor in FCS whose
nature and mode of action is at present under investigation.
DISCUSSION
In this report we provide evidence that cells from the autono-
mously growing human Burkitt lymphoma cell line RAJI are
still susceptible to control mechanisms exerted through the C3d/
EBV receptor, CR2, whose engagement has been shown to
promote the progression through the S-phase in the case of
normal murine B cells (Melchers et al., 1985). We also show that
human C3d can stimulate human B cells under these conditions
and that stimulation can occur via other epitopes on CR2 than
the C3d-binding site.
We used a cell culture system that employed bovine serum
albumin as the sole source ofprotein. The BSA used in this study
was a commercially available Cohn V fraction that was not
purified any further before use and could therefore still contain
some impurities that might have been important for cell growth.
In this cell culture system addition of purified C3d or C3dg as
well as monoclonal antibodies to CR2 led to an enhanced
proliferation, as demonstrated both by an increased TdR
incorporation (Fig. 3) and an increase in cell number (Figs 1 and
2). Although the stimulatory effect of antibodies to CR2 has
been noted previously by other authors (Nemerow et al., 1985a;
Frade et al., 1985b) and ourselves (Petzer et al., 1988), the
experimental system used in this study offers the advantage of
working with a homogenous cell population and therefore we
can be certain that the observed stimulatory effects are not due
to an indirect effect mediated by a small number of contaminat-
ing cells. The direct stimulatory effect of several ligands of
CR2-C3 fragments as well as antibodies to various epitopes on
CR2-on pre-activated B cells therefore seems firmly estab-
lished.
Assuming a previously postulated model of the control of B-
cell proliferation (Melchers et al., 1985), one would speculate,
on the basis of the results presented here, that the two
'restriction points' in the B-cell cycle, which are normally
overcome by stimulation of the antigen receptor and by the
action ofa T-cell-derived growth factor, must be non-functional
or bypassed on RAJI cells. Stimulation of B cells and T cells by
mitogens, PMA, ionomycin or antibody to the CD3 molecule,
i.e. agents that render the cell competent to respond to
'progression factors' (e.g. IL-2), is known to induce the
expression ofc-myc (Kelly et al., 1983; Reed, Nowell & Hoover,
1985). RAJI cells are known to express c-myc (Maguire et al.,
1983) and it would be interesting to examine whether the
expression of c-myc could be responsible for rendering a B cell
responsive to stimulation via CR2. In addition RAJI cells
produce an autocrine factor (Gordon et al., 1984a, b; Blazar et
al., 1983) which could perhaps replace the progression factor
normally provided by T cells.
Simultaneous use of two monoclonal antibodies to different
epitopes of CR2 did not lead to the stimulation observed with
either antibody alone. Whether this reflects the possibility that a
particular way of cross-linking CR2 on the surface of the cell
abrogates stimulation is unclear at present. In the case of the
TI 1 antigen (CD2) it has been shown previously that only
antibodies to certain epitopes produced a stimulation when used
in combination, whereas others did not (Meuer et al., 1984).
RAJI cells grown in serum-containing media express five to 10-
fold more CR2 than RAJI cells grown under serum-free
conditions. This increase in CR2 does not seem to be induced by
C3 present in culture media, as addition ofC3d or of antibodies
against CR2 to the serum-free culture did not enhance the
expression of CR2. CR2 therefore does not seem to belong to
the group of receptors that are up-regulated by their own ligand.
The biochemical nature and the mode of action of the putative
serum factor that induces the expression of CR2 is at present
under investigation. While this study was in progress, other
workers (Hatzfield et al., 1988) have also noted the stimulatory
effect of C3d on RAJI cells grown in serum-free culture.
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